PL2435093T3 - Koniugaty albumina-peptyd amyloidu oraz ich zastosowania - Google Patents

Koniugaty albumina-peptyd amyloidu oraz ich zastosowania

Info

Publication number
PL2435093T3
PL2435093T3 PL10724360.2T PL10724360T PL2435093T3 PL 2435093 T3 PL2435093 T3 PL 2435093T3 PL 10724360 T PL10724360 T PL 10724360T PL 2435093 T3 PL2435093 T3 PL 2435093T3
Authority
PL
Poland
Prior art keywords
albumin
amyloid peptide
peptide conjugates
conjugates
amyloid
Prior art date
Application number
PL10724360.2T
Other languages
English (en)
Inventor
Barrio J. Manuel Sarasa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of PL2435093T3 publication Critical patent/PL2435093T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL10724360.2T 2009-05-26 2010-05-26 Koniugaty albumina-peptyd amyloidu oraz ich zastosowania PL2435093T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09382078A EP2258398A1 (en) 2009-05-26 2009-05-26 Albumin-amyloid peptide conjugates and uses thereof

Publications (1)

Publication Number Publication Date
PL2435093T3 true PL2435093T3 (pl) 2016-11-30

Family

ID=41022577

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10724360.2T PL2435093T3 (pl) 2009-05-26 2010-05-26 Koniugaty albumina-peptyd amyloidu oraz ich zastosowania

Country Status (19)

Country Link
US (2) US9023991B2 (pl)
EP (2) EP2258398A1 (pl)
JP (2) JP5936539B2 (pl)
KR (1) KR101459080B1 (pl)
CN (1) CN102458478B (pl)
AR (1) AR076892A1 (pl)
AU (1) AU2010251961B2 (pl)
BR (1) BRPI1011314A2 (pl)
CA (1) CA2763569C (pl)
DK (1) DK2435093T3 (pl)
ES (1) ES2587962T3 (pl)
HU (1) HUE030218T2 (pl)
IL (1) IL216626A (pl)
MX (1) MX2011012677A (pl)
PL (1) PL2435093T3 (pl)
PT (1) PT2435093T (pl)
RU (1) RU2533806C2 (pl)
TW (1) TWI524900B (pl)
WO (1) WO2010136487A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013021353A1 (en) * 2011-08-11 2013-02-14 Bar-Ilan University Surface modified proteinaceous spherical particles and uses thereof
CN103450347A (zh) * 2012-05-29 2013-12-18 四川百利药业有限责任公司 一种用于治疗阿尔兹海默症的多肽及基因疫苗
CN105315361A (zh) * 2014-07-29 2016-02-10 天津大学 一种酸化白蛋白及制备方法和在抑制β-淀粉样蛋白聚集的应用
ES2571055B1 (es) * 2016-02-15 2016-12-28 Araclon Biotech, S.L. Conjugado amiloide y usos y procedimientos del mismo
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
CN115715809A (zh) * 2022-11-24 2023-02-28 武汉禾元生物科技股份有限公司 重组人血清白蛋白-药物偶联物
KR20250125186A (ko) * 2024-02-14 2025-08-21 국립부경대학교 산학협력단 알부민 고정 셀룰로오스 및 이를 포함하는 알츠하이머 치료용 조성물

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610493B1 (en) 1993-06-17 2003-08-26 Brigham And Women's Hospital Screening compounds for the ability to alter the production of amyloid-β peptide
US5955317A (en) 1993-01-25 1999-09-21 Takeda Chemical Industries, Ltd. Antibodies to β-amyloids or their derivatives and use thereof
JP4374316B2 (ja) * 1993-01-25 2009-12-02 武田薬品工業株式会社 β−アミロイドまたはその誘導体に対する抗体およびその用途
EP0683234B2 (en) * 1993-01-25 2007-06-06 Takeda Chemical Industries, Ltd. Antibody against beta-amyloid or their derivative and use thereof
US7427392B1 (en) 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
SI0994728T1 (sl) 1997-04-09 2009-02-28 Intellect Neurosciences Inc Rekombinantna protitelesa, specifična za beta-amiloidne konce, kodirana z DNA ter postopki za njihovo uporabo
US6809186B1 (en) 1999-01-22 2004-10-26 Martek Biosciences Corporation Simple method for labeled conjugate production
US6849714B1 (en) 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
WO2001062284A2 (en) 2000-02-21 2001-08-30 Pharmexa A/S Novel method for down-regulation of amyloid
US6926898B2 (en) * 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
US6787636B1 (en) 2000-07-14 2004-09-07 New Century Pharmaceuticals, Inc. Modified serum albumin with reduced affinity for nickel and copper
EP1975179A1 (en) * 2001-12-26 2008-10-01 Araclon Biotech, S.L. Polyclonal antibodies, preparation method thereof and use of same
US8877901B2 (en) 2002-12-13 2014-11-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates
AU2003259965A1 (en) 2002-08-20 2004-03-11 Neurogenetics, Inc. Methods and compositions for modulating amyloid beta
CA2508831C (en) 2002-12-13 2012-05-01 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
ES2246177B1 (es) 2003-05-08 2007-03-01 Universidad De Zaragoza. Uso de anticuerpos para el tratamiento de enfermedades amiloideas.
US20050255042A1 (en) 2003-11-24 2005-11-17 The Regents Of The University Of California Office Of Technology Transfer, University Of California On-demand cleavable linkers for radioconjugates for cancer imaging and therapy
SI2336147T1 (sl) 2003-12-17 2014-08-29 Janssen Alzheimer Immunotherapy Konjugati nosilcev a beta imunogenih peptidov in postopki izdelave istih
CN101665538A (zh) 2003-12-18 2010-03-10 诺沃挪第克公司 与白蛋白样物质相连的新glp-1类似物
JP2007522119A (ja) * 2004-01-28 2007-08-09 キュリックス エーピーエス アミロイド関連疾患用ワクチンとしてのアミロイドタンパク質のコンジュゲート
WO2005116260A2 (en) 2004-05-25 2005-12-08 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
CA2604032C (en) 2005-04-06 2017-08-22 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
WO2006121656A2 (en) * 2005-05-05 2006-11-16 Merck & Co., Inc. Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease
CA2607056C (en) 2005-10-19 2015-11-24 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
US8106015B2 (en) * 2007-04-20 2012-01-31 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Method for enhancing immune response with peptide

Also Published As

Publication number Publication date
HK1164168A1 (zh) 2012-09-21
PT2435093T (pt) 2016-08-08
RU2011153023A (ru) 2013-07-10
CN102458478B (zh) 2014-03-19
US20140086945A1 (en) 2014-03-27
US20120130049A1 (en) 2012-05-24
AU2010251961A1 (en) 2011-12-22
WO2010136487A1 (en) 2010-12-02
JP2015096512A (ja) 2015-05-21
JP5985589B2 (ja) 2016-09-06
DK2435093T3 (en) 2016-08-15
CA2763569A1 (en) 2010-12-02
MX2011012677A (es) 2011-12-16
US9163062B2 (en) 2015-10-20
CA2763569C (en) 2014-10-28
ES2587962T3 (es) 2016-10-27
TWI524900B (zh) 2016-03-11
IL216626A (en) 2016-10-31
TW201109033A (en) 2011-03-16
HUE030218T2 (en) 2017-04-28
JP5936539B2 (ja) 2016-06-22
AR076892A1 (es) 2011-07-13
EP2435093B1 (en) 2016-06-29
RU2533806C2 (ru) 2014-11-20
US9023991B2 (en) 2015-05-05
BRPI1011314A2 (pt) 2016-03-15
CN102458478A (zh) 2012-05-16
EP2258398A1 (en) 2010-12-08
EP2435093A1 (en) 2012-04-04
AU2010251961B2 (en) 2013-11-28
KR101459080B1 (ko) 2014-11-07
IL216626A0 (en) 2012-02-29
JP2012528111A (ja) 2012-11-12
KR20120052906A (ko) 2012-05-24

Similar Documents

Publication Publication Date Title
ZA201109324B (en) Multimeric peptide conjugates and uses thereof
ZA201104497B (en) Peptide therapeutic conjugates and uses thereof
SG10201801503XA (en) e-POLYLYSINE CONJUGATES AND USE THEREOF
IL221278A0 (en) Chlorotoxin polypeptides and conjugates and uses thereof
GB0916576D0 (en) Polypeptides and uses thereof
SG2014012918A (en) Albumin variants and conjugates
GB0916578D0 (en) Polypeptides and uses thereof
SI2483292T1 (sl) Variantni polipeptidi lovd in njihove uporabe
IL216626A0 (en) Albumin-amyloid peptide conjugates and uses thereof
IL220536A0 (en) Anti - bv8 antibodies and uses thereof
LT2300033T (lt) Kolageno peptido konjugatai ir jų panaudojimas
PL2464656T3 (pl) Nowy peptyd i jego zastosowanie
GB0908515D0 (en) Peptide
IL214527A0 (en) Anti-mst1r antibodies and uses thereof
GB0818065D0 (en) Immunogenic peptides and uses thereof
ZA201203722B (en) Peptide
WO2011087491A9 (en) Parstatin peptides and uses thereof
EP2415780A4 (en) SYNTHETIC PEPTIDE AND USES THEREOF
GB0906023D0 (en) Insulin-Nanoparticle conjugates
GB0906115D0 (en) Antibody and uses thereof
HK1168612A (en) Multimeric peptide conjugates and uses thereof
GB0816561D0 (en) Peptides and uses thereof
GB0800502D0 (en) Peptides and their uses
GB0903746D0 (en) Novel conjugated proteins and peptides
GB0909494D0 (en) Neuroprotective peptide